Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa

Franck Danel, Lucinda M. C. Hall, Brigid Duke, Deniz Gur, David M. Livermore
Franck Danel
Antibiotic Group, Department of Medical Microbiology, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, E1 2AD, United Kingdom, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucinda M. C. Hall
Antibiotic Group, Department of Medical Microbiology, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, E1 2AD, United Kingdom, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigid Duke
Antibiotic Group, Department of Medical Microbiology, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, E1 2AD, United Kingdom, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deniz Gur
Section of Infectious Diseases, Department of Internal Medicine, Hacettepe University School of Medicine, 06100 Ankara, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Livermore
Antibiotic Group, Department of Medical Microbiology, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, London, E1 2AD, United Kingdom, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.6.1362
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Nucleotide and protein sequences of the coding region of OXA-17 β-lactamase in comparison to those of OXA-10, -11, -14, and -16 enzymes. The nucleotide sequence shown in full corresponds to that determined in this study and was allocated the GenBank accession no. AF060206. Nucleotide differences in otherblaOXA-10 family genes are marked above theblaOXA-17 sequence, and the deduced amino acid changes are indicated below. The signal peptide extends from amino acid residues 1 to 20, and the proposed cleavage site is shown by a vertical line. The underlined nucleotide sequences represent the primers ABD1, ABD2, ABD3, and ABD4 used for PCR amplification or sequencing. The sequences corresponding to the amplification primers have not been independently determined for OXA-17 and are shown in italics. The three conserved elements previously described in class D β-lactamase are in boldface (14, 17).

Tables

  • Figures
  • Table 1.

    MICs of β-lactams for P. aeruginosa isolates 871 and 873

    StrainMIC (μg/ml)a
    PipPip-ClavPip-TazCbCb-ClavCb-TazCazCaz-ClavCaz-TazCtxCtrCslCpmCprCpzMoxAztMemImp
    8713232321,0242565121281664641281283264128321280.52
    873643264>512512>512128163212812864163212864640.254
    PU21(pMLH57)/PER-1b8485121282562564128641281283264321612812
    PU21244646464422161622888412
    • ↵a Azt, aztreonam; Cb, carbenicillin; Clav, clavulanate at 4 μg/ml; Cpm, cefepime; Cpr, Cefpirome; Cpz, cefoperazone; Csl, cefsulodin; Ctx, cefotaxime; Caz, ceftazidime; Ctr, ceftriaxone; Imp, imipenem; Mem, meropenem; Mox, moxalactam (latamoxef); Pip, piperacillin; Taz, tazobactam at 4 μg/ml.

    • ↵b P. aeruginosa PU21 with pMLH57 plasmid coding PER-1 β-lactamase.

  • Table 2.

    Characteristics of E. coli XL1-blue MRF′ transformants selected with ampicillin (10 μg/ml) from the DNA libraries of isolates 871 and 873 in the pBC SK+ vector

    LibraryNo. of coloniesPlasmid size (kb)aβ-Lactam-ase pIHybridi-zationPlasmid
    Isolate 873
     HindIII10107.9blaOXA-2p13A
    296.1blaOXA-10p13F
     BamHI4117.9blaOXA-2p13D
     PstI2106.1blaOXA-10p13E
    Isolate 871
     HindIII17107.9blaOXA-2p15A
    696.1blaOXA-10p15D
     BamHI4186.1blaOXA-10p15C
     PstI0NAbNANANA
    • ↵a The vector pBC SK+ had a size of 3.4 kb.

    • ↵b NA, not applicable.

  • Table 3.

    MICs for representative E. coli XL1-blue transformants with ampicillin resistance cloned from isolates 871 and 873

    Plasmid and β-lactamase transformantaMIC (μg/ml)b
    AmpPipPip-ClavPip-TazCbCb-ClavCb-TazCazCaz-ClavCaz-TazCtxCtrCslCpimCpzMoxAztImp
    p15C/OXA-17 from isolate 871512812512641280.50.250.50.51640.516110.06
    p13E/OXA-17 from isolate 8735128145126425610.50.50.51640.516210.12
    p15A/OXA-2 from isolate 871256160.120.255128410.250.250.120.06320.1280.250.060.06
    p13A/OXA-2 from isolate 87312820.50.251288410.120.50.060.6160.1220.120.120.06
    XL1-blue(p10A)/OXA-1051216181,0241281280.250.120.250.120.5320.2580.2510.06
    XL1-blue (no plasmid)40.250.120.128480.250.120.250.060.06160.120.120.120.120.06
    • ↵a Into E. coli XL1-blue.

    • b Amp, ampicillin; Azt, aztreonam; Cb, carbenicillin; Clav, clavulanate at 4 μg/ml; Cpim, cefepime; Cpz, cefoperazone; Csl, cefsulodin; Ctx, cefotaxime; Caz, ceftazidime; Ctr, ceftriaxone; Imp, imipenem; Mox, moxalactam (latamoxef); Pip, piperacillin and Taz, tazobactam at 4 μg/ml.

  • Table 4.

    Kinetic parameters for OXA-17 β-lactamase compared with OXA-10

    SubstrateOXA-17 (linear kinetics)OXA-10a
    Km (μM)kcat(s−1)kcat/KmbVssVo
    Km(s−1)kcat(s−1)kcat/KmbKm(μM)kcat(s−1)kcat/Kmb
    Penicillin G34 ± 0.6c5 ± 0.114763 ± 689 ± 101,412−d−−
    Ampicillin245 ± 3726 ± 0.2106235 ± 30587 ± 302,50077 ± 9531 ± 126,896
    Carbenicillin296 ± 312 ± 0.421195 ± 1331 ± 1159370 ± 44126 ± 5340
    Oxacillin153 ± 13120 ± 2.0784222 ± 16608 ± 10273996 ± 8660 ± 106,870
    Cloxacillin573 ± 7920 ± 1.0352,640 ± 323520 ± 361961,110 ± 1002,682 ± 1502,416
    Cephaloridine2,940 ± 18223 ± 1.082,340 ± 30079 ± 833395 ± 8339 ± 398
    Cephalothin286 ± 605 ± 0.11738 ± 26 ± 0.1158−−−
    Cefotaxime2,240 ± 42722 ± 3.010346 ± 199 ± 0.226−−−
    Ceftriaxone544 ± 521 ± 0.05255 ± 23 ± 0.354−−−
    CeftazidimeNDeNDNDNDND−−−−
    • ↵a OXA-10 β-lactamase was shown previously (8) to give biphasic kinetics, so two sets of kinetics parameters could be determined for the initial (Vo) and steady-state (Vss) phases of hydrolysis.

    • ↵b (kcat/Km) × 1,000 in micromolar−1 second−1.

    • ↵c Values are means ± standard error.

    • ↵d −, results not available.

    • ↵e ND, hydrolysis not detected.

PreviousNext
Back to top
Download PDF
Citation Tools
OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa
Franck Danel, Lucinda M. C. Hall, Brigid Duke, Deniz Gur, David M. Livermore
Antimicrobial Agents and Chemotherapy Jun 1999, 43 (6) 1362-1366; DOI: 10.1128/AAC.43.6.1362

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
OXA-17, a Further Extended-Spectrum Variant of OXA-10 β-Lactamase, Isolated from Pseudomonas aeruginosa
Franck Danel, Lucinda M. C. Hall, Brigid Duke, Deniz Gur, David M. Livermore
Antimicrobial Agents and Chemotherapy Jun 1999, 43 (6) 1362-1366; DOI: 10.1128/AAC.43.6.1362
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Pseudomonas aeruginosa
beta-lactamases

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596